Trevena (TRVN) Competitors $0.25 +0.24 (+2,400.00%) As of 09/17/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. PTPI, HEPA, BPTH, BPTSY, BON, PBLA, VINC, NCNA, NAVB, and SYRSShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Petros Pharmaceuticals (PTPI), Hepion Pharmaceuticals (HEPA), Bio-Path (BPTH), Biophytis (BPTSY), Bon Natural Life (BON), Panbela Therapeutics (PBLA), Vincerx Pharma (VINC), NuCana (NCNA), Navidea Biopharmaceuticals (NAVB), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors Petros Pharmaceuticals Hepion Pharmaceuticals Bio-Path Biophytis Bon Natural Life Panbela Therapeutics Vincerx Pharma NuCana Navidea Biopharmaceuticals Syros Pharmaceuticals Petros Pharmaceuticals (NASDAQ:PTPI) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Is PTPI or TRVN more profitable? Trevena's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Trevena N/A N/A -119.55% Does the media favor PTPI or TRVN? In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment Petros Pharmaceuticals Neutral Trevena Neutral Do analysts prefer PTPI or TRVN? Trevena has a consensus price target of $5.00, indicating a potential upside of 1,900.00%. Given Trevena's stronger consensus rating and higher possible upside, analysts clearly believe Trevena is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, PTPI or TRVN? Petros Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Do insiders & institutionals believe in PTPI or TRVN? 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 8.2% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, PTPI or TRVN? Petros Pharmaceuticals has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.16-$8.16M-$52.910.00Trevena$443K0.54-$40.29M-$47.04-0.01 SummaryTrevena beats Petros Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$240K$857.31M$5.78B$10.28BDividend YieldN/A4.84%5.74%4.64%P/E Ratio-0.011.2076.9426.98Price / Sales0.5426.49543.88128.54Price / CashN/A19.5637.1760.63Price / Book-0.026.7013.836.37Net Income-$40.29M-$4.03M$3.29B$271.46M7 Day PerformanceN/A-1.48%1.57%2.53%1 Month Performance-9.09%10.17%6.87%9.42%1 Year Performance-94.68%19.18%81.59%30.16% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena1.7237 of 5 stars$0.25+2,400.0%$5.00+1,900.0%N/A$240K$443K-0.0140Gap UpPTPIPetros Pharmaceuticals0.2112 of 5 stars$0.03-1.7%N/A-99.7%$901K$5.11M-0.0120Gap DownHEPAHepion Pharmaceuticals0.9569 of 5 stars$0.08+14.7%N/A-99.8%$885KN/A-0.0220Negative NewsBPTHBio-Path0.523 of 5 stars$0.09-17.5%N/A-94.3%$773KN/A0.0010Negative NewsShort Interest ↑Gap DownBPTSYBiophytisN/A$2.00flatN/A-59.5%$702KN/A0.0030BONBon Natural Life1.1173 of 5 stars$1.83+18.8%N/AN/A$311K$23.84M0.00100Gap DownHigh Trading VolumePBLAPanbela Therapeutics0.07 of 5 stars$0.05-66.7%N/A-84.8%$243KN/A0.006Gap DownVINCVincerx Pharma3.4862 of 5 stars$0.04-11.6%$40.00+113,860.1%-99.7%$184KN/A0.0060Negative NewsGap DownNCNANuCana0.8278 of 5 stars$2.91+0.7%N/A-99.4%$87KN/A0.0030NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-90.0%$50K$8.13K0.0010SYRSSyros Pharmaceuticals4.2992 of 5 stars$0.00-45.5%$1.00+83,233.3%-100.0%$32K$386K0.00120Gap Down Related Companies and Tools Related Companies PTPI Alternatives HEPA Alternatives BPTH Alternatives BPTSY Alternatives BON Alternatives PBLA Alternatives VINC Alternatives NCNA Alternatives NAVB Alternatives SYRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVN Stock Alerts